CureVac NV

CVAC53

Penny Stock

$2.75arrow_drop_down4.86%-$0.13

Penny Stock

CVAC53

$2.75

arrow_drop_down4.86%-$0.13

Penny Stock

Performance History

Key Stats
Open	$2.88
Prev. Close	$2.84
EPS	-1.34
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$625.83M
PE Ratio	-

	LOW	HIGH
Day Range	2.73	2.93
52 Week Range	2.21	6.34

Ratios







EPS	-1.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About CureVac NV (CVAC)

CureVac NV (CVAC) is a biopharmaceutical company that focuses on developing innovative medicines based on messenger RNA (mRNA) technology. The company's mission is to harness the power of mRNA to revolutionize the treatment of severe diseases. CureVac NV is headquartered in Tübingen, Germany, and has a strong global presence with subsidiaries and research facilities in various countries.

CureVac NV's stock price history has been subject to fluctuations in response to various market and industry dynamics. Investors can track the performance of CVAC stock to stay informed about its price movements. It is important to note that past performance is not indicative of future results, and investors should conduct thorough analysis before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Alexander Zehnder M.B.A., M.D.
Headquarters: Tübingen
Employees: 904
Exchange: NASDAQ

Keep an eye on CureVac NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is CureVac NV's (CVAC) price per share?

The current price per share for CureVac NV (CVAC) is $2.75. The stock has seen a price change of -$0.14 recently, indicating a -4.86% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for CureVac NV (CVAC)?

For CureVac NV (CVAC), the 52-week high is $6.34, which is 130.55% from the current price. The 52-week low is $2.22, the current price is 24.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is CureVac NV (CVAC) a growth stock?

CureVac NV (CVAC) has shown an average price growth of -3.13% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying CureVac NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is CureVac NV (CVAC) stock price performance year to date (YTD)?

As of the latest data, CureVac NV (CVAC) has a year-to-date price change of -34.37%. Over the past month, the stock has experienced a price change of -2.48%. Over the last three months, the change has been -16.92%. Over the past six months, the figure is -7.41%.

help

Is CureVac NV (CVAC) a profitable company?

CureVac NV (CVAC) has a net income of -$254.83M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -493.58% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $52.66M, although specific revenue growth data is currently not available. Operating income is noted at -$276.22M. Furthermore, the EBITDA is -$287.12M.

help

What is the market capitalization of CureVac NV (CVAC)?

CureVac NV (CVAC) has a market capitalization of $617.99M. The average daily trading volume is 2.8, indicating the stock's liquidity and investor engagement.

News

MRNA

CANCER VACCINES

THERAPEUTICS

PERSONALIZED MEDICINE

MULTIVALENT VACCINES

Oct 14, 2024

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

SIMTRA BIOPHARMA SOLUTIONS

CDMO

STERILE INJECTABLES

DR. LIDIA SERINA

PHARMACEUTICAL INDUSTRY

Aug 27, 2024

Simtra BioPharma Solutions ernennt Dr. Lidia Serina zum Head of Development Services

May 23, 2024

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

May 23, 2024

Wall Street Breakfast Podcast: Nvidia Soars On Strong Earnings, Guidance, And Stock Split

Jan 26, 2024